Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2000-11-13
2004-03-16
Scheiner, Laurie (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S208100, C536S023720
Reexamination Certificate
active
06706268
ABSTRACT:
The invention relates to cloned DNA sequences indistinguishable from genomic RNA and DNA of lymphadenopathy-associated virus (LAV), a process for their preparation and their uses. It relates more particularly to stable probes including a DNA sequence which can be used for the detection of the LAV virus or related viruses or DNA proviruses in any medium, particularly biological samples containing any of them. The invention also relates to polypeptides, whether glycosylated or not, encoded by said DNA sequences.
Lymphadenopathy-associated virus (LAV) is a human retrovirus firs't isolated from the lymph node of a homosexual patient with lymphadenopathy syndrome, frequently a prodrome or, a benign form of acquired immune deficiency syndrome (AIDS). Subsequently other LAV isolates have been recovered from patients with AIDS or pre-AIDS. All available data are consistent with the virus being the causative agent of AIDS.
A method for cloning such DNA sequences has already been disclosed in British Patent Application Nr. 84 23659 filed on Sep. 19, 1984. Reference is here-after made to that application as concerns subject matter in common with the further improvements to the invention disclosed herein.
The present invention aims at providing additional new means which should not only also be useful for the detection of LAV or related viruses (hereafter more generally referred to as “LAV viruses”), but also have more versatility, particularly in detecting specific parts of the genomic DNA of said viruses whose expression products are not always directly detectable by immunological methods.
The present invention further aims at providing polypeptides containing sequences in common with polypeptides encoded by the LAV genomic RNA. It relates even more particularly to polypeptides comprising antigenic determinants included in the proteins encoded and expressed by the LAV genome occuring in nature. An additional object of the invention is to further provide means for the detection of proteins related to LAV virus, particularly for the diagnosis of AIDS or pre-AIDS or, to the contrary, for the detection of antibodies against the LAV virus or proteins related therewith, particularly in patients afflicted with AIDS or pre-AIDS or more generally in asymtomatic carriers and in blood-related products. Finally the invention also aims at providing immunogenic polypeptides, and more particularly protective polypeptides for use in the preparation of vaccine compositions against AIDS or related syndroms.
The present invention relates to additional DNA fragments, hybridizable with the genomic RNA of LAV as they will be disclosed hereafter, as well as with additional cDNA variants corresponding to the whole genomes of LAV viruses. It further relates to DNA recombinants containing said DNAs or cDNA fragments.
The invention relates more particularly to a cDNA variant corresponding to the whole of LAV retroviral genomes, which is characterized by a series of restriction sites in the order hereafter (from the 5′ end to the 3′ end).
The coordinates of the successive sites of the whole LAV genome (restriction map) are indicated hereafter too, with respect to the Hind III site (selected as of coordinate 1) which is located in the R region. The coordinates are estimated with an accuracy of ±200 bp:
Hind III
0
Sac I
50
Hind III
520
Pst I
800
Hind III
1 100
Bgl II
1 500
Kpn I
3 500
Kpn I
3 900
Eco RI
4 100
Eco RI
5 300
Sal I
5 500
Kpn I
6 100
Bgl II
6 500
Bgl II
7 600
Hind III
7 850
Bam HI
8 150
Xho I
8 600
Kpn I
8 700
Bgl II
8 750
Bgl II
9 150
Sac I
9 200
Hind III
9 250
Another DNA variant according to this invention optionally contains an additional Hind III approximately at the 5 550 coordinate.
Reference is further made to
FIG. 1
which shows a more detailed restriction map of said whole-DNA (&lgr;J19).
An even more detailed nucleotidie sequence of a preferred DNA according to the invention is shown in
FIGS. 4-12
hereafter.
The invention further relates to other preferred DNA fragments which will be referred to hereafter.
REFERENCES:
patent: 4520113 (1985-05-01), Gallo et al.
patent: 4629783 (1986-12-01), Cosand
patent: 4708818 (1987-11-01), Montagnier et al.
patent: 4725669 (1988-02-01), Essex et al.
patent: 4808536 (1989-02-01), Chang et al.
patent: 5001230 (1991-03-01), Brown et al.
patent: 5156949 (1992-10-01), Luciw et al.
patent: 0 113 078 (1984-07-01), None
patent: 0115 459 (1984-08-01), None
patent: 0 199 301 (1986-10-01), None
patent: 245 459 (1987-11-01), None
patent: 0258404 (1988-03-01), None
patent: WO 84/04327 (1984-11-01), None
patent: WO 87/05399 (1987-09-01), None
patent: WO 91/04051 (1991-04-01), None
Scheupbach et al., “Serological Analysis of a Subgroup of Human T-Lymphotropic Retroviruses (HTLV-III) Associated with AIDS,” Science, 224:503-505 (1984).
Kalyanaraman et al., “Antibodies to the Core Protein of Lymphadenopathy-Associated Virus (LAV) in Patients with AIDS,” Science, 225:321-323 (1984).
Robey et al., “Characterization of Envelope and Core Structural Gene Products of HTLV-III with Sera from AIDS Patients,” Science, 228:593-595 (1985).
Allan et al., “Major Glycoprotein Antigens That Induce Antibodies in AIDS Patients are Encoded by HTLV-III,” Science, 228, 1091-1094 (1985).
Crowl et al., “HTLV-III Env Gene Products Synthesized inE. coliare Recognized by Antibodies Present in the Sera of AIDS Patients,” Chemical Abstracts, 103, p. 190, No. 154983e (1985).
Montagnier et al., “Identification and Antigenicity of the Major Envelope Glycoprotein of Lymphadenopathy-Associated Virus,” Chemical Abstracts, 103, p. 263, No. 34641v (1985).
Weiss et al., “Neutralization of Human T-lymphotropic Virus Type III by Sera of AIDS and AIDS-Risk Patients,” Nature, 316:69-72 (1985).
Barin et al., “Virus Envelope Protein of HTLV-III Represents Major Target Antigen for Antibodies in AIDS Patients,” Science, 228:1094-1096 (1985).
Wain-Hobson et al., “Nucleotide Sequence of the AIDS Virus, LAV,” Cell, 40:9-17 (1985).
Muesing et al., “Nucleic Acid Structure and Expression of the Human AIDS/Lymphadenopathy Retrovirus,” Nature, 313:450-458 (1985).
Schneider et al., “A Glycopolypeptide (gp 100) is the Main Antigen Detected by HTLV-III Antiserums,” Chemical Abstracts, 103, p. 430, No. 52370k (1985).
Sarngadharan et al., “Immunological Properties of HTLV-III Antigens Recognized by Sera of Patients with AIDS and AIDS-Related Complex and of Asymptomatic Carriers of HTLV-III Infection,” Chemical Abstracts, 103, p. 551, No. 121329t (1985).
Alizon et al., “Molecular Cloning of Lymphadenopathy-Associated Virus,” Nature, 312:757-760 (1984).
Chang et al., “An HTLV-III Peptide Produced by Recombinant DNA is Immunoreactive with Sera from Patients with AIDS,” Nature, 315:151-154 (1985).
Chang et al., “Detection of Antibodies to Human T-Cell Lymphotropic Virus-III (HTLV-III) with an Immunoassay Employing a RecombinantEscherichia Coli-Derived Viral Antigenic Peptide,” Biotechnology, 3:905-909 (1985).
Ratner et al., “Complete Nucleotide Sequence of the AIDS Virus, HTLV-III,” Nature, 313:277-284 (1985).
Dreesman et al., “Antibody to Hepatitis B Surface Antigen after a Single Inoculation of Uncoupled Synthetic HbsAg Peptides,” Nature, 295:158-160 (1982).
Kitchen et al., “Aetiology of AIDS-Antibodies to Human T-Cell Leukemia Virus (Type III) in Hemophiliacs,” Nature, 312:367-369 (1984).
Essex et al., “Antibodies to Cell Membrane Antigens Associated with Human T-Cell Leukemia Virus in Patients with AIDS,” Science, 220:859-862 (1983).
Seiki et al., “Human Adult T-Cell Leukemia Virus: Complete Nucleotide Sequence of the Provirus Genome Integrated in Leukemia Cell DNA,” Proc. Natl. Acad. Sci. USA, 80:3618-3622 (1983).
“Centorcor Unveils R-DNA AIDS Assay; Faces FDA,” Biotechnol. Newswatch, vol. 5, p. 3, Abstract No. 03-10-003226 (1985).
Arya et al., “Homology of Genome of AIDS-Associated Virus with Genomes of Human T-Cell Leukemia Viruses,” Science, 225:927-930 (1984).
Kamlekar, S. et al., Science, 262:1680-1685 (1993).
Guy, B. et al., Nature, 330:266-269 (1987).
Lawrence, J., 1988, “Update: HIV-1 Gene No
Alizon Marc
Danos Oliver
Sonigo Pierre
Stewart Cole
Wain-Hobson Simon
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Institut Pasteur
Parkin Jeffrey S.
Scheiner Laurie
LandOfFree
Human deficiency virus type-1 (HIV-1) peptide encoded by the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human deficiency virus type-1 (HIV-1) peptide encoded by the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human deficiency virus type-1 (HIV-1) peptide encoded by the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3247262